{"entity":{"id":"proceade-crc-03","kind":"trial","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","aka":["PROCEADE-CRC-03"],"tldr":"A phase 3 trial testing Precemtabart tocentecan in colorectal cancer, now recruiting.","summary":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) is a phase 3 interventional study registered as NCT07549412, led by EMD Serono Research & Development Institute with Merck KGaA, Darmstadt, Germany, and recruiting on the registry. Official title: A Randomised, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03). Planned enrolment is 1020 participants (estimated). The study started in 2026-05-06 and primary completion is expected in 2029-10-16. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07549412","url":"https://clinicaltrials.gov/study/NCT07549412"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["precemtabart-tocentecan"],"companies":["merck-kgaa"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07549412","phase":"3","setting":"A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","sponsor":"EMD Serono Research & Development Institute","participation":[{"nct":"NCT07549412","source":"https://clinicaltrials.gov/study/NCT07549412","fetchedAt":"2026-10-07T16:55:48.292Z","studySha256":"a095ada26e1a38b245e535220ec26730bba4e4a88d13f42b324cf114dde33569","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-09","leadSponsor":"EMD Serono Research & Development Institute, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1020,"enrolmentType":"ESTIMATED","siteCount":66,"recruitingSiteCount":66,"countries":["Argentina","Australia","Austria","Belgium","Canada","China","France","Germany","Hong Kong","Japan","Poland","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2026-05-06","startedType":"actual","enrolled":1020,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/proceade-crc-03/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","route":"/drugs/precemtabart-tocentecan/"}],"company":[{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"}]}}